Vertical RAS-pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations

Key Points

• Therapeutically exploitable mitochondrial alterations arise from RAS-pathway inhibition in pancreatic cancer.
• Inhibition of KRAS can alter metabolic rewiring, and dual targeting of SHP2 and MAPK may prove beneficial.
• The approach involves targeting metabolic adaptations that drive resistance to current therapies in PDAC.
• These findings highlight the need for further exploration into SHP2/MAPK inhibition's impact on cancer resistance.